iX Biopharma cuts loss in FY 2025

The group’s revenue grew by 30% year on year to $7.7m.

iX Biopharma has narrowed its loss to $10.1m for the financial year 2025, compared to a $10.8m loss during the same period last year.

The group’s revenue grew by 30% year on year to $7.7m. Despite weaker consumer spending in Australia, Speciality Pharmaceuticals grew its revenue by 22% driven by strong sales of medicinal cannabis products and services in Australia.

The Nutraceuticals segment also grew more than twofold, primarily from new engagements in the PRC, USA, Europe and the Middle East.

Despite higher revenue, the group’s cost of sales increased due to a different revenue mix and economies of scale.

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia